Article Text

AB0698 MID-Term Effects of Rituximab in Connective Tissue Disorders Related Interstitial Lung Disease (ILD)
  1. G. Lepri1,2,
  2. J. Avouac1,
  3. P. Airò3,
  4. F. Anguita Santos4,
  5. S. Bellando Randone2,
  6. J. Blagojevic2,
  7. O. Distler5,
  8. F.J. Garcìa Hernàndez6,
  9. J.A. Gonzalez Nieto7,
  10. S. Guiducci2,
  11. S. Jordan5,
  12. V. Limaye8,
  13. B. Maurer5,
  14. V. Riccieri9,
  15. A. Selva-O'Calaghan10,
  16. M. Matucci Cerinic2,
  17. Y. Allanore1
  1. 1Paris Descartes University, Paris, France
  2. 2University of Florence, Florence
  3. 3University of Brescia, Brescia, Italy
  4. 4Hospital Clinico San Cecilio, Granada, Spain
  5. 5University Hospital Zurich, Zurich, Switzerland
  6. 6University Hospital Virgen del Rocio, Seville
  7. 7Hospital de Can Misses, Ibiza, Spain
  8. 8Royal Adelaide Hospital, Adelaide, Australia
  9. 9University of Rome, La Sapienza, Rome, Italy
  10. 10Vall D'Hebron General Hospital, Barcelona, Spain


Background The treatment of ILD remains a challenge for the rheumatologist. Recent studies suggested a potential short-term benefit of rituximab (RTX) on connective tissue diseases developing ILD.

Objectives To compare RTX effects on ILD in patients with systemic sclerosis (SSc), mixed connective tissue disorder (MCTD) and anti-synthetase (SYN).

Methods Multicentre retrospective assessment of the effects of RTX on ILD comparing three patient populations: SSc (n=23), MCTD (n=6) and SYN (n=15). All underwent high-resolution computed tomography (HRCT) at baseline and lung function tests (LFTs) at baseline and at 1 and 2 years of follow-up. The primary outcomes were the mean change in predicted forced vital capacity (FVC) value and the percentage of responders defined by an increase in FVC of 10% or greater.

Results In SYN patients, although the change of FVC from baseline to 2 years was not statistically significant, a trend of improvement was observed (table 1). In SSc, discrepancies were observed with a trend of improvement at 1 year but a decline at 2 years. In MCTD, FVC remained table at 1 and 2 years of follow-up. In SYN patients, the percentage of responders for FVC was greater than in SSc (33.3% vs 9.5%) (p=0.1) and than in MCTD patients (33.3% vs 16.7%) (p=0.15). At baseline, SSc and MCTD patients had a higher FVC when compared to SYN population (table 1) and this finding may partially explain the major percentage of responders in SYN than in SSc. The percentage of responders in DLCO (gain ≥15%) was similar in SYN and SSc populations (27.3% and 23.8% respectively). Some patients received DMARDs and/or immunosuppressive treatment previously or/and concurrently to RTX; although this did not influence our findings, these treatments may influence the effects of RTX. RTX showed a satisfactory safety profile.

Conclusions Our data obtained in routine care provide for the first time outcomes in LFTs after 2 years of follow-up. The main results show a good safety profile supporting future development. We also observed a promising trend of improvement in the SYN group and indicate that the drug may provide a stabilization of the involvement of the lung in SSc and MCTD. Future trials on homogenous groups of patients are warranted to determine how rituximab may be positioned in the treatment of CTD-ILD, but the SYN group should be prioritized.

Acknowledgements EULAR scintific travel bursary

Disclosure of Interest G. Lepri: None declared, J. Avouac: None declared, P. Airò: None declared, F. Anguita Santos: None declared, S. Bellando Randone: None declared, J. Blagojevic: None declared, O. Distler Grant/research support from: received research funding from, 4D Science, Actelion, Active Biotec, Bayer-Schering, Biogen, Biovitrium, BMS, Boehringer Ingelheim Pharma, EpiPharm, Ergonex, GSK, Inventiva, Medac, Novartis, Pfizer, Pharmacyclics, Roche/Genentech, Sanofi/Genzyme, Serodapharm, Sinoxa and United BioSource Corporation., F. J. Garcìa Hernàndez: None declared, J. A. Gonzalez Nieto: None declared, S. Guiducci: None declared, S. Jordan: None declared, V. Limaye: None declared, B. Maurer: None declared, V. Riccieri: None declared, A. Selva-O'Calaghan: None declared, M. Matucci Cerinic: None declared, Y. Allanore Grant/research support from: received research funding in relationship with the treatment of systemic sclerosis from Actelion, Bayer, Biogen Idec, BMS, Genentech/Roche, Inventive, Medac, Pfizer, Sanofi/Genzyme, Servier and UCB

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.